More MS news articles for February 2000

Pathobiotek Reports New Product - Quantitative PCR for Bloodborne Bacteria

Tuesday February 1, 8:06 am Eastern Time
Company Press Release
SOURCE: Pathobiotek Diagnostics Inc.

HOUSTON, Feb. 1 /PRNewswire/ -- Pathobiotek Diagnostics Inc. (OTC Bulletin Board: PBTK - news), a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, Tuesday announced that significant progress has been made in the development of a more accurate method of quantitation of the bloodborne bacteria, working name Luey. This latest advancement in the PCR products enables testing directly from serum samples.

Elevation of levels of Luey has been seen in patients with MS and other immune disorders. The establishment of a precise quantitation method of Luey in MS patients could lead to a less costly, more decisive and defined diagnosis than is currently available. The most widely accepted diagnosis for MS depends on subjective symptomatic observations and often expensive testing, including Magnetic Resonance Imaging (MRI). Pathobiotek's advancement in this area could significantly impact the future of immune disease diagnostics.

Quantitative serum PCR was developed by research scientists at Pathobiotek to provide a more precise method of measurement. This new tool provides accurate data on the level of living bacteria in an individual based on the quantitation of the genetic material, ribonucleic acid (RNA), instead of DNA. This method is very sensitive and is needed to determine total amounts of Luey in healthy vs. non-healthy individuals. This quantitative PCR process can be automated to screen a large number of samples in a short time period.

Quantitative PCR of Luey is one of Pathobiotek's primary objectives and now it can be used for better correlation studies than have been possible earlier. Researchers involved in this process are working diligently to adapt this new tool to studies to study Luey's role in MS and other immune disorders. The new quantitative PCR reagents and procedure will be available in kit form. (See the Pathobiotek website soon.)

Safe Harbor Statement: Except for historical information contained herein, the matters set forth in this news release are forward-looking statements. Forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those identified in the company's filings with the Securities and Exchange Commission.

SOURCE: Pathobiotek Diagnostics Inc.